Literature DB >> 10146976

Pharmacoeconomic consequences of measurement and modification of hospital drug use.

L L Ioannides-Demos1, G M Eckert, A J McLean.   

Abstract

Patterns of drug usage affect hospital-based delivery of healthcare in a variety of ways. Adverse reactions to drugs (ADR) precipitate some 5% of admissions and prejudice the care of some 20% of patients who are in hospital, while inadequate drug therapy prejudices outcomes and prolongs hospital stay. Conversely, appropriate application of drugs can promote recovery and increase the quality of care. Well documented examples include prevention of deep vein thrombosis and postoperative wound infections. Accordingly, optimisation of drug use represents a major quality assurance issue in addition to determining cost-efficiency of healthcare delivery. Drug utilisation review (DUR) requires all elements of the quality assurance process. In practice, therapeutically meaningful and cost-efficient exercises can only be mounted if there is knowledge of the linkage between patterns of drug use and clinical outcomes. These processes of measurement are currently rate-limiting in quality assurance. There are various ways that hospital drug usage can be measured. These range from readily available and relatively cheap quantitative methods to methods requiring the availability of expert staff. There is a sequence of methods involving increasing costs and increasing resource demands yielding increasing detail of information obtained. This sequence commences with pharmacy purchases, followed by pharmacy issues to particular clinical areas, prescription or treatment sheet survey, clinical record review, and finally the reports of trained investigators working in the clinical area. The simpler methods can provide useful information and an efficient basis for choosing and planning definitive studies. Once a category of drug use is appropriately targeted for intervention, drug use can be modified by planned intervention with improvement in clinical outcomes and reduced economic costs in many instances. The intervention strategies to modify drug usage may be classed as re-educative, persuasive, facilitative and power strategies. Other models for implementing behavioural change have been considered, including the impact of trained investigators and the use of online computer prescribing with interactive software with appropriate guidelines. The challenge is to achieve sustained change when interventions are implemented. Cost-efficient quality assurance of drug use is possible with modest resources if outcome-orientated activities are prioritised.

Entities:  

Mesh:

Year:  1992        PMID: 10146976     DOI: 10.2165/00019053-199202010-00004

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  173 in total

Review 1.  Computers in healthcare: overview and bibliography.

Authors:  J F Dasta; M L Greer; S M Speedie
Journal:  Ann Pharmacother       Date:  1992-01       Impact factor: 3.154

2.  Measuring and modifying hospital drug use.

Authors:  G M Eckert; L L Ioannides-Demos; A J McLean
Journal:  Med J Aust       Date:  1991-05-06       Impact factor: 7.738

3.  Trends in prescribing of antihypertensive drugs in Australia, 1977-1987.

Authors:  S F Hurley; S L Williams; J J McNeil
Journal:  Med J Aust       Date:  1990-03-05       Impact factor: 7.738

4.  Prescribing costs when computers are used to issue all prescriptions.

Authors:  J B Donald
Journal:  BMJ       Date:  1989-07-01

5.  Measurement of cost-effectiveness of drug therapy: a review of the treatment of hypertension.

Authors:  R F Moulds
Journal:  Med J Aust       Date:  1990-08-06       Impact factor: 7.738

6.  Quality control of hospital formularies.

Authors:  T D Rucker
Journal:  Pharm Weekbl Sci       Date:  1988-08-19

7.  Short term metronidazole therapy contrasted with povidone-iodine spray in the prevention of wound infection after appendicectomy.

Authors:  R J Salem; J Johnson; P Devitt
Journal:  Br J Surg       Date:  1979-06       Impact factor: 6.939

8.  Methods of record linking.

Authors:  N C Robertson; J A Baldwin; D J Hall
Journal:  J Chronic Dis       Date:  1971-07

9.  Adverse drug reactions during hospitalization.

Authors:  R I Ogilvie; J Ruedy
Journal:  Can Med Assoc J       Date:  1967-12-09       Impact factor: 8.262

10.  Effect of aminoglycoside-use restrictions on drug cost.

Authors:  O H DeTorres; R E White
Journal:  Am J Hosp Pharm       Date:  1984-06
View more
  9 in total

Review 1.  Economic impact of cost-containment strategies in third party programmes in the US. Part II.

Authors:  C M Kozma; R M Schulz; W M Dickson; J T Dye; E R Cox; D A Holdford; L Michael; W N Yates; T L Young
Journal:  Pharmacoeconomics       Date:  1993-09       Impact factor: 4.981

2.  The formulary decision-making process in a US academic medical centre.

Authors:  D B Nash; M L Catalano; C J Wordell
Journal:  Pharmacoeconomics       Date:  1993-01       Impact factor: 4.981

Review 3.  Drug utilisation review and pharmacoeconomics: interaction after parallel development?

Authors:  S Garattini; G Tognoni
Journal:  Pharmacoeconomics       Date:  1993-09       Impact factor: 4.981

Review 4.  Drug utilisation studies as tools in health economics.

Authors:  J A Sacristán; J Soto
Journal:  Pharmacoeconomics       Date:  1994-04       Impact factor: 4.981

5.  Approaches to rationing drugs in hospitals. An Australian perspective.

Authors:  F Bochner; N G Burgess; E D Martin
Journal:  Pharmacoeconomics       Date:  1996-11       Impact factor: 4.981

Review 6.  Cephalosporin utilisation review and evaluation.

Authors:  G M Misan; C Dollman; D R Shaw; N Burgess
Journal:  Pharmacoeconomics       Date:  1995-08       Impact factor: 4.981

Review 7.  Antimicrobial drug utilisation in hospitals in Italy and other European countries.

Authors:  L Guglielmo; R Leone; U Moretti; A Conforti; G P Velo
Journal:  Infection       Date:  1994       Impact factor: 3.553

8.  Drug rationing in a teaching hospital.

Authors:  A J McLean; L L Ioannides-Demos; N Tong; D Topliss
Journal:  BMJ       Date:  1994-07-02

9.  Risk assessment of drug interaction potential and concomitant dosing pattern on targeted toxicities in pediatric cancer patients.

Authors:  Jeffrey S Barrett; Dimple Patel; Erin Dombrowsky; Gaurav Bajaj; Jeffrey M Skolnik
Journal:  AAPS J       Date:  2013-04-18       Impact factor: 4.009

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.